Tempus AI to Acquire Personalis for $1.5 Billion to Expand MRD Precision Oncology Monitoring

Tempus AI has entered into a definitive agreement to acquire Personalis in a transaction with an enterprise value of approximately $1.5 billion (net of Tempus’ existing stake). Personalis shareholders will receive $16.25 per share, with consideration primarily structured as Tempus stock and Tempus having the option to pay up to 50% in cash. The deal is expected to close in late 2026 or early 2027, subject to shareholder approval, regulatory clearances, and customary closing conditions.